Search research articles
Contact Us
Filters
Showing results (181-190 of 302) with videos related to
Page
of 31
Sort By:
International Journal of Cancer
|
September 8, 2011
Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study
Pascal Jézéquel, Loïc Campion, Frédérique Spyratos, et al.
The Lancet. Oncology
|
November 6, 2012
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot, Gilles Romieu, Mario Campone, et al.
Breast Cancer Research and Treatment
|
March 16, 2016
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano, Gilles Romieu, Mario Campone, et al.
Breast Cancer Research : BCR
|
November 23, 2014
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer
Sébastien Toffoli, Isabelle Bar, Fadi Abdel-Sater, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
Fabrice André, Thomas Bachelot, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Sara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2017
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, et al.
Clinical Breast Cancer
|
September 23, 2018
Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, et al.
British Journal of Cancer
|
June 12, 2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature
Solenn Barraud, Sophie Vacher, Camille Schiffler, et al.
Page
of 31
Search research articles
Search
Showing results (181-190 of 302) with videos related to
Sort By:
Page
of 31
International Journal of Cancer
|
September 8, 2011
Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study
Pascal Jézéquel, Loïc Campion, Frédérique Spyratos, et al.
The Lancet. Oncology
|
November 6, 2012
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot, Gilles Romieu, Mario Campone, et al.
Breast Cancer Research and Treatment
|
March 16, 2016
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano, Gilles Romieu, Mario Campone, et al.
Breast Cancer Research : BCR
|
November 23, 2014
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer
Sébastien Toffoli, Isabelle Bar, Fadi Abdel-Sater, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
Fabrice André, Thomas Bachelot, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Sara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2017
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, et al.
Clinical Breast Cancer
|
September 23, 2018
Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, et al.
British Journal of Cancer
|
June 12, 2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature
Solenn Barraud, Sophie Vacher, Camille Schiffler, et al.
Page
of 31